Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer

다국어 초록 (Multilingual Abstract)

We report on a 64-year-old man with leptomeningeal metastasis (LM) from an epidermal growth factor receptor (EGFR)-mutated adenocarcinoma of the lung. He was treated with paclitaxel, cisplatin. After completion of chemotherapy, he complained of headache, nausea, and vomiting. EGFR-mutated tumor cells were identified from the cerebrospinal fluid (CSF). Second-line therapy with gefitinib, methotrexate was started. After receiving gefitinib for 4 weeks, he had no more headaches or vomiting. Eleven months after initiation of gefitinib, he developed headache and nausea. Chest computed tomography showed aggravation of bone metastasis. Third-line therapy was started with gemcitabine and carboplatin. Two weeks later, he experienced disorientation. After a fourth relapse within the central nervous system, the therapy was switched to erlotinib and significant improvement of LM was achieved. This case shows that LM can be diagnosed by detecting EGFR mutation in CSF and EGFR tyrosine kinase inhibitors are effective for LM from EGFR mutant non-small cell lung cancer.

참고문헌 (Reference)

1 이계영, "비소세포폐암에서 PNA-Mediated PCR Clamping을 이용한 EGFR 돌연변이 분석법" 대한결핵및호흡기학회 69 (69): 271-278, 2010

2 Aisner DL, "The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities" 40 : 511-524, 2012

3 Tokumo M, "The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers" 11 : 1167-1173, 2005

4 Jackman DM, "Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with highdose gefitinib" 24 : 4517-4520, 2006

5 O’Meara WP, "Leptomeningeal metastasis" 31 : 367-424, 2007

6 Choong NW, "Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation" 3 : 50-57, 2006

7 Kim MK, "Gefitinib is also active for carcinomatous meningitis in NSCLC" 50 : 265-269, 2005

8 Katayama T, "Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib" 4 : 1415-1419, 2009

9 Wasserstrom WR, "Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients" 49 : 759-772, 1982

10 Shingyoji M, "Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis" 6 : 1215-1220, 2011

11 Kim HR, "Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping" 32 : 50-, 2013

12 Kim HJ, "Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer" 75 : 321-325, 2012

13 Kim HJ, "Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients" 5 : 271-276, 2013

14 Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib" 350 : 2129-2139, 2004

15 Glantz MJ, "A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt)to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors" 5 : 3394-3402, 1999